Entero Therapeutics (NASDAQ:GRDX – Get Free Report) released its earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.04 million for the quarter.
Entero Therapeutics Stock Performance
GRDX traded up $0.29 during trading on Wednesday, reaching $3.59. 26,565 shares of the company traded hands, compared to its average volume of 118,570. Entero Therapeutics has a 12-month low of $1.87 and a 12-month high of $6.93. The firm has a fifty day simple moving average of $4.27 and a 200 day simple moving average of $3.62. The company has a market cap of $25.60 million, a P/E ratio of -1.89 and a beta of 1.67.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Entero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th.
Get Our Latest Research Report on Entero Therapeutics
Entero Therapeutics Company Profile
Entero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency. Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency.
Read More
- Five stocks we like better than Entero Therapeutics
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
